Home Antibody All anti-STK17A antibodies
Also for STK17A (NM_004760)
|DRAK1 antibody was raised against a peptide corresponding to amino acids near the amino terminus of human DRAK1.|
||ELISA, WB: 1 ug/ml, ICC: 2 ug/ml, IF: 10 ug/ml
|PBS containing 0.02% sodium azide.|
|Affinity chromatography purified via peptide column
|Homo sapiens serine/threonine kinase 17a (STK17A)|
|Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 for DAP kinase-related apoptosis-inducing protein kinases (1). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK1 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK1 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues (1).|
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of DRAK1 in (A) MOLT4 and (B) A431 whole cell lysates with DRAK1 antibody at 1 ug/mL.
Immunocytochemistry staining of MOLT4 cells using DRAK1 antibody at 2 ug/mL.